UBS Group
AKCA

UBS Group’s Akcea Therapeutics Inc AKCA Stock Holding History

UBS Group’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-551
Closed -$10K – 9170
2020
Q3 		$10K Buy
551
+215
+64% +$3.05K ﹤0.01% 6903
2020
Q2 		$5K Sell
336
-433
-56% -$6.68K ﹤0.01% 7417
2020
Q1 		$11K Buy
+769
New +$12.6K ﹤0.01% 6908
2019
Q4 		– Sell
-27,244
Closed -$419K – 8625
2019
Q3 		$419K Buy
27,244
+27,044
+13,522% +$576K ﹤0.01% 4707
2019
Q2 		$5K Hold
200
– – ﹤0.01% 7415
2019
Q1 		$6K Hold
200
– – ﹤0.01% 7123
2018
Q4 		$6K Sell
200
-2,921
-94% -$81.9K ﹤0.01% 7511
2018
Q3 		$109K Buy
3,121
+2,902
+1,325% +$87.8K ﹤0.01% 5527
2018
Q2 		$5K Buy
219
+19
+10% +$454 ﹤0.01% 7499
2018
Q1 		$5K Sell
200
-62
-24% -$1.33K ﹤0.01% 7270
2017
Q4 		$4K Sell
262
-31
-11% -$608 ﹤0.01% 7491
2017
Q3 		$8K Buy
+293
New +$5.42K ﹤0.01% 7027

UBS Group's AKCA Position: Q4 2020 in Review

UBS Group sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 551 shares — an estimated $10K sold.

UBS Group first reported a position in AKCA in Q3 2017 and held it in 12 quarters. The position peaked at $419K in Q3 2019. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • UBS Group reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • UBS Group sold 551 Akcea Therapeutics Inc shares in Q4 2020, an estimated $10K.
  • UBS Group first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 12 quarters.
  • UBS Group's Akcea Therapeutics Inc position peaked at $419K in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.